What Should We Tell Our Patients About Marijuana?

There have been questions from several practitioners lately about marijuana what you should tell your clients about it. In this article from the Integrative Medicine Clinician’s Journal, Joseph Pizzorno, ND. discusses a variety of issues around marijuana that you should be aware of, and then explain to your clients.

Abstract
With several states allowing medicinal use of marijuana and a growing number decriminalizing recreational use, many of our patients are using this herbal drug. Approximately 43% of US adults have tried marijuana, with 13% using it regularly. These users are seeking help from integrative medicine practitioners regarding safety. They are looking for advice based on research and clinical experience, not politics or philosophical bias.

The major health problems caused by marijuana appear to be bronchial irritation, decreased motivation, learning difficulties, and injuries. However, less well appreciated are the toxicity problems caused by contamination with pesticides and solvent residues. We have important guidance to help prevent unnecessary toxicity in our patients who choose to use marijuana. This editorial reviews toxicity and safety. Medicinal use will be addressed in the future.

Long-time readers of IMCJ are well aware of the many editorials I have written on how a growing body of research is showing that toxins have become a major cause of chronic disease. As I study toxicity, my understanding has broadened to include not only environmental metals and chemicals but also endogenously produced toxins such as those from homocysteine, gut bacteria and nonoptimally detoxified hormones. To this list I now add what I call “toxins of choice.”

Few of our patients are intentionally exposing themselves to neurotoxic organophosphate pesticides, endocrine disrupting polychlorinated biphenyls (PCBs), insulin receptor site-blocking phthalates, or lung-damaging mold from damp buildings. However, many of our patients are intentionally consuming known toxins such as alcohol and marijuana and are unlikely to realize that at modest dosages, salt, high-fructose corn syrup, phosphates, and nonsteroidal anti-inflammatory drugs (NSAIDs) are toxic as well. Added to this that by also considering genetic susceptibility, even sources of gluten, can be toxic.

The huge load of environmental, endogenous, and choice toxins add up to deplete stores of protective glutathione and cause physiological and structural damage in many ways.

Table 1 shows my current list of the many toxins that stress physiology and cause disease in our patients. Where I have written an editorial on the topic, the issue is included in parentheses.

Table 1. The Many Sources of Toxins

Exogenous Toxins

OTC and prescription drugs (see editorial in IMCJ 7(3))

Chemicals

Inorganic

Organic

Fluoride

Persistent organic pollutants (see editorial in IMCJ 12(2))

Solvents

Metals

Arsenic

Cadmium

Lead

Mercury (see editorial in IMCJ 8(1), 8(2), 9(4))

Microbial

Mold (damp building, 15.2, 15.3)

Particulate matter

Radiation

Light at night

Medical

Cell phoneEndogenous

Catecholamines, if COMT SNP

Gut-derived toxins

Homocysteine (see editorial in IMCJ 6(4))

Non-end product metabolites

Poorly detoxified hormonesToxins of Choice

Alcohol (see editorial in IMCJ 11.(6))

Marijuana (see editorial in IMCJ 15(6))

Food constituents

High-fructose corn syrup

Phosphates

Salt (see editorial in IMCJ 14(1))

Smoking

Wheat, if zonulin producer (see editorial in IMCJ 12(6))

Cannabis (Marijuana)

Although the federal government has classified Cannabis as a controlled substance illegal for use, many states have now decriminalized its use. Twenty-four states and the District of Columbia have passed laws allowing medicinal use of marijuana and 14 states have decriminalized its use. The percentage of Americans who say they have tried marijuana has steadily increased from 4% in 1969 to 43% in 2016.1

Cannabis production has become a multibillion-dollar industry in the United States, and legal markets for cannabis are projected to reach $11 billion by 2019.2 The federal illegality of Cannabis has resulted in not only limited clinical research but also a production environment with few standards and very little regulation. As most is currently grown indoors, heavy use of agricultural chemicals is common. Toxicity may be due to not only constituents of marijuana itself, but also contaminants such as solvents, pesticides, and heavy metals with most extracts adding solvent residues. This likely helps explain some of the discrepancies in the research.

Toxicity

Unadulterated Cannabis

Almost 500 compounds have been extracted from Cannabis, of which 65 are classified as cannabinoids. The most abundant cannabinoids include delta-9-tetrahydrocannabinoic acid (THCA), cannabidiolic acid (CBDA), cannabigerolic acid (CBGA), and their decarboxylated derivatives delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol (CBG).3

These compounds are converted into their more active decarboxylated counterparts by heat (smoking, evaporation, baking), light, or natural degradation. THC is the most psychoactive component of cannabis and alters cognition primarily through the activation of CB1 receptors on presynaptic axons, though several other mechanisms have been identified.4,5 The content of THC in marijuana has increased from 3.1% in 1992 to 5.1% in 2002.7

THC itself has low toxicity and modest use has shown minimal long-term physical or psychological effects when not used to excess.8,9 Acute high dose intoxication occurs quickly but is short term. Typical symptoms include nausea, anxiety, paranoia, short-term memory loss, confusion, and disorientation.10 THC impairs gonadal function by blocking gonadotropin-releasing hormone (GnRH) release. This results in lower levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which causes reduced testosterone production by the testicular Leydig cells.11

The research on the toxicity of whole plant marijuana is inconsistent, probably due to lack of control for contaminants, poor assessment of dosage, small sample sizes, limited number of heavy users, mode of use, and not adjusting for other factors such as alcohol, tobacco, and other recreational drugs.12

The method of use significantly affects the toxicity of marijuana. The most common use is inhalation of the smoke of the dried plant. This results in higher risk for adverse effects.13 The whole-plant smoke contains many hazardous compounds such as ammonia, cyanide, heavy metals, carbon monoxide, mutagens, carcinogens, and polycyclic aromatic hydrocarbons.14Surprisingly, the tar from a Cannabis cigarette contains higher concentrations of carcinogens such as benzanthracenes and benzopyrenes than does tobacco smoke.15

Contaminants

Pesticides

For most of the 20th century, the majority of marijuana produced in the United States was grown outdoors. With more aggressive law enforcement, marijuana agriculture moved indoors. Although this provided the benefit of year-round cultivation, it also required the use of agricultural chemicals, typically synthetic fertilizers and pesticides.

Because Cannabis cultivation is illegal, there are no pesticides registered for use on Cannabisin the United States, meaning there is little research on their use for this purpose.16 The limited research suggests that this results in higher chemical residue levels.17There are apparently no direct studies on how pesticides in Cannabis affects consumers of the product. Table 2 shows a list of the toxic contaminants that have been found in both medical and recreational marijuana. Research has shown that Cannabis extracts (see Solvents section below) contain considerable amounts of pesticides.18

Table 2. Toxic Agricultural Chemicals Found in Cultivated Marijuana 19,20,21,22

PesticidesBifenthrin, chlorpyrifos, diazinon, methamidophos, teflubenzuronFungicidesTebuconazoleGrowth regulatorEthephonMosquito repellantDEET, Malathion

Abbreviation: DEET, N,N-diethyl-meta-toluamide.

Solvents

Many methods are used to concentrate the active constituents in Cannabis. The organic solvents benzene, hexane, naphtha, petroleum ether, and butane pose a significant risk of toxic chemical concentration.23 Hexane and benzene are neurotoxic, and naptha and petroleum ether are potential carcinogens. Research has shown significant residues in these products.24 A process called dabbing uses butane to produce higher THC content.25

Safer alternative methods of concentration use ethanol and olive oil. Perhaps best is the use of supercritical CO2 to extract volatile oils from Cannabis as this leaves no residue. Although there is limited research on the efficacy of these methods, nontoxic solvents are clearly preferable.

Heavy metals

Cannabis has been shown to be especially effective in absorbing metals such as cadmium and copper from contaminated soils.26 Making matters worse, Cannabis is also intentionally contaminated with metals to increase the market weight. In 2008, 150 people in Germany developed lead poisoning as the result of using adulterated cannabis.27

Microbial

Indoor growth results in increased susceptibility of Cannabis to contamination by microbes such as fungi, bacteria, and plant viruses. Growing and drying also increase the risk of microbial contamination.28 Penicillium species are the predominant microbe contamination in marijuana grown indoor.29 Cannabis has even been shown to be contaminated with human pathogens such as hepatitis A30 hepatitis B31 and salmonella.32 Chronic pulmonary aspergillosis has been found in immunocompromised individuals using medicinal marijuana.33

Synthetic Cannabinoids

There is limited research on synthetic cannabinoids (SCBs) such as “Spice,” “K2,” “herbal incense,” and others. Toxicity reports include tachycardia, hypertension, tachypnea, chest pain, heart palpitations, hallucinations, racing thoughts, and seizures.34 The most common clinical signs of toxicity are neurologic including agitation, central nervous system depression/coma, and delirium/toxic psychosis.35 There have been reports of acute renal failure associated with the use of these synthetic analogues.36 These compounds appear significantly more toxic than cannabis and should be avoided.37

Detoxification

The liver metabolizes THC through hydroxylation and oxidation reactions catalyzed by cytochrome P450 enzymes, especially CYP2C9 and CYP3A4.38,39,40 Approximately 65% is excreted in the feces and 20% in urine.41 THC is excreted in the urine primarily as the glucuronic acid conjugate THCCOOH, which has a half-life between 30 and 44 hours.42

Clinical Indications of Toxicity

Long-term smoking of marijuana leaf has been shown to cause airway obstruction43; squamous metaplasia44; impaired psychomotor performance; increased incidence of schizophrenia45; cancer of the mouth, jaw, tongue, and lung; and leukemia in children of marijuana smoking mothers.46 Although marijuana smoke has been shown to contain carcinogenic compounds, research is unclear about whether a link with lung cancer exists.47
Population studies in adults show that heavy cannabis use increases the risk of accidents, can produce dependence and has been associated with poor social outcomes and mental health.48 Long-term daily use has been associated with decreased motivation, impaired ability to learn, and reduced sexual desire.49,50 Daily heavy inhalation can produce bronchial irritation and may lead to long-term pulmonary damage secondary to the associated hydrocarbon residues.51

Intervention

As noted previously, marijuana can be considered a “toxin of choice.” This means dosage and toxicity are under the control of the user. Abstinence is, of course, the most effective way to decrease cannabis toxicity. However, for most patients, management to prevent excessive use and education to choose the least toxic forms is more likely. Research has shown little benefit treating cannabis dependence with prescription drugs such as selective serotonin reuptake inhibitor (SSRI) antidepressants, mixed-action antidepressants, atypical antidepressants (bupropion), anxiolytics (buspirone), and norepinephrine reuptake inhibitors.52
N-acetyl-cysteine (NAC) at 1200 mg BID has shown benefits because its induction of glutathione synthesis helps mitigate many of the toxic effects and improve the odds of abstinence.53,54

Vaporization (“vaping”) of extracts appears the preferred method of use as it reduces respiratory exposure to toxic particulates and carcinogens.55 For those smoking the dried plant (buds, leaf, flowers, etc), the type of filtration significant affects toxic chemical residue. Hand-held glass pipes allow the most toxins, unfiltered water pipes are intermediate, and the lowest quantity is found with filtered water pipes.56 Heating may make many of contaminants more toxic.57

Conclusion

Many of our patients are using, and in some cases abusing Cannabis. Our key clinical responsibility is to help those who choose to use marijuana “for whatever reason” to do so responsibly and as safely as possible. The most common ways of obtaining and using marijuana clearly result in clinical toxicity. Interestingly, most of this toxicity appears to be determined by contaminants and the consumption method.

We need to advise our patients to carefully avoid marijuana which is contaminated with agricultural chemicals, metals, microbes, solvents, etc. In addition, damage can be decreased by recommending the least toxic ways of consuming marijuana. Because the primary psychoactive constituent of marijuana, THC, appears to have little toxicity (though it likely plays a major role in the psychological issues), our guidance should focus on ways to limit exposure to everything else. This suggests recommending organically grown product, CO2 extraction, and vaporization rather than smoking the agricultural chemical-laced dried plant.

Joseph Pizzorno, ND, Editor in Chief
Innovative Medicine Clinician’s Journal
drpizzorno@innovisionhm.com
twitter: @drpizzorno

References

1. Gallop. One in eight U.S. adults say they smoke marijuana. Retrieved from http://www.gallop.com/poll/194195/. Published 2016. Accessed December 2, 2016.
2. ArcView Market Research. The State of Legal Marijuana Markets. 3rd ed. San Francisco, CA: ArcView Market Research; 2016.
3. Happyana N, Agnolet S, Muntendam R, et al. Analysis of cannabinoids in laser-microdissectedtrichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR. Phytochemistry. March 2013;87:51-59.
4. Wilson R, Nicoll R. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-682.
5. Hejazi N, Zhou C, Oz M, Sun H, Ye JH, Zhang L. Delta-9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol. 2006;69(3):991-997.
6. Elsohly MA, Ross SA, Mehmedic Z, et al. Potency trends of delta-9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci. 2000;45:24-30.
7. National Center for the Development of Natural Products. Quarterly Report, Potency Monitoring Project/NIDA Marijuana Project. Oxford, MS: University of Mississippi, Research Institute of Pharmaceutical Sciences, School of Pharmacy; 2003.
8. Smith DE, Mehl C. An analysis of marijuana toxicity. Clin Toxicol. 1970;3(1):101-105.
9. Smith DE. The acute and chronic toxicity of marijuana. J Psych drugs. 1968;2(1):37-47.
10. Weil A. Adverse reactions to marijuana: Classification and suggested treatment. N Engl J Med. 1970;282:997-1000.
11. Harclerode J. Endocrine effects of marijuana in the male: Preclinical studies. NIDA Res Monograph. 1984;44:46-64.
12. Hashibe M, Straif K, Tashkin DP, Morgenstren H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk. Alcohol. 2005;35(3):265-275.
13. Cohn A, Johnson A, Ehlke S, Villanti A. Characterizing substance use and mental health profiles of cigar, blunt, and non-blunt marijuana users from the National Survey of Drug Use and Health. Drug Alcohol Depend. March 2016;160:105-111.
14. Moir D, Rickert W, Levasseur G, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol. 2008;21(2):494-502.
15. Wu TC, Scott R, Burnett S, et al. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med. 1988;318:347-351.
16. Thomson J. Medical Marijuana Cultivation and Policy Gaps. Sacramento, CA: California Research Bureau; 2012.
17. Stone D. Cannabis, pesticides and conflicting laws: The dilemma for legalized states and implications for public health. Reg Toxicol Pharmacol. 2014;69(3):284-288.
18. Raber JC, Elzinga S, Kaplan C. Understanding dabs: Contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci. 2015;40(6):797-803.
19. Thompson C, Sweitzer R, Gabriel M, Purcell K, Barrett R, Poppenga R. Impacts of rodenticide and insecticide toxicants from marijuana cultivation sites on fisher survival rates in the Sierra National Forest, CA. Conserv Letter. 2014;7:91-102.
20. Perez-Parada A, Alonso B, Rodriguez C, et al. Evaluation of three multiresidue methods for the determination of pesticides in marijuana (Cannabis sativa L) with liquid chromatography-tandem mass spectrometry. Chromatographia. 2016;79(17):1069-1083.
21. United Chemical Technologies. Potency and pesticide content in medical vs. recreational marijuana. Amchro Web site. http://www.amchro.com/uct/Potency_and_Pesticide_Content_in_Medical_vs._Recreational_Marijuana_0_6101-02-01.pdf. Published 2015. Accessed December 8, 2016..
22. Skeet N. City attorney explains medical marijuana issue on NBC. LA City Attorney Web site. http://lacityorgatty.blogspot.com/2009/10/city-attorney-explains-medical.html. Published October 10, 2009. Accessed December 2, 2016.
23. Rosenthal E, Downs D. Beyond Buds: Marijuana Extracts—Hash, Vaping, Dabbing, Edibles, and Medicines. San Francisco, CA: Quick American Archives; 2014.
24. Romano L, Hazekamp A. Cannabis oil: Chemical evaluation of an upcoming cannabis based medicine. Cannabinoids. 2013;1(1):1-11.
25. Miller BL, Stogner JM, Miller JM. Exploring butane hash oil use: a research note. J Psychoactive Drug. 2016;48(1):44-49.
26. Kozlowski R. Interview with Professor R. Kozlowski, director of the Institute of Natural Fibers. J Int Hemp Assoc. 1995;2(2):86-87.
27. Busse F, Omidi L, Timper K, et al. Lead poisoning due to adulterated marijuana. N Engl J Med. 2008;358(15):1641-1642.
28. Miller JD, Johnson L. Consequences of large-scale production of marijuana in residential buildings. Indoor Built Environ. 2012;21:595-600.
29. Martyny JW, Serrano K, Schaeffer J, Van Dyke M. Potential exposures associated with indoor marijuana growing operations. J Occup Environ Hygiene. 2013;10(11):622-639.
30. Alexander T. Hepatitis outbreak linked to imported pot. Sinsemilla Tips. 1987;7(3):22.
31. Cates W, Warren JW. Hepatitis B in Nuremburg, Germany. JAMA. 1975;234:930-934.
32. Taylor DN, Washsmuth IK, Shangkuan YH, et al. Salmonellosis associated with marijuana. N Engl J Med. 1981;306:1249-1253.
33. Gargani Y, Bishop P, Denning DW. Too many moldy joints: Marijuana and chronic pulmonary aspergillosis. Mediterr J Hematol Infect Dis. 2011;3(1):e2011005.
34. Wells DL, Ott CA. The ‘new” marijuana. Ann Pharmacother. 2011;45(3):414-417.
35. Riederer AM, Campleman SL, Carlson RG, et al. Acute poisonings from synthetic cannabinoids: 50 US toxicology investigators consortium registry sites, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(27):692-695.
36. Gudsoorkar VS, Perez JA Jr. A new differential diagnosis: Synthetic cannabinoids-associated acute renal failure. Methodist Debakey Cardiovasc J. 2015;11(3):189-191.
37. Bonnet U, Mayler H. Synthetic cannabinoids: Spread, addiction biology, and current perspective of personal health hazard. Fortschr Neurol Psychiatr. 2015;83(4):221-231.
38. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: Clinical implications. Iran J Psychiatr. 2012;7(4):149-156.
39. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007;80(15):1415-1419.
40. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. Drug Metab Rev. 2014;46(1):86-95.
41. Lemberger L, Axelrod J, Kopin IJ. Metabolism and disposition of delta-9-tetrahydrocannabinol in man. Pharmacol Rev. 1971;23:371-380.
42. Goulle JP, Saussereau E, Lacroix C. Delta-9-tetrahydrocannabinol pharmacokinetics. Ann Pharm Fr. 2008;66(4):232-244.
43. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol. 2002;42(11 Suppl):715-815.
44. Zhang ZF, Morgenstern H, Spitz MR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 1999;8(12):1071-1078.
45. Kelley M, Wan C, Broussard B, et al. Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophrenia Res. 2016;171(1):62-67.
46. Robison LL, Buckley JD, Daigle AE, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. Cancer. 1989;63(10):1904-1911.
47. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1829-1834.
48. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction. 2015;110(1):19-35.
49. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yergelun-Todd D. Cognitive measures in long-term cannabis users. J Clin Pharmacol. 2002;42(1 Suppl):41S-47S.
50. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337-1343.
51. Bloom JW, Kaltenborn W, Paoletti P, Camilli A, Lebowitz M. Respiratory effects of non-tobacco cigarettes. Br Med J. 1987:295(6612):1516-1518.
52. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2014;12:CD008940.
53. Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev. August 2015;55:294-321.
54. Asevedo E, Mendes AC, Berk M, Brietzke E. Systematic review of N-acetylcysteine in the treatment of addictions. Rev Bras Psiquiatr. 2014;36(2):168-175.
55. Tashkin DP. How beneficial is vaping cannabis to respiratory health compared to smoking? Addiction. 2015;110(11):1706-1707.
56. Sullivan N, Elzinga S, Raber J. Determination of pesticide residues in cannabis smoke. J Toxicol. 2013;2013:378168.
57. Lorenz W, Bahadir M, Korte F. Thermolysis of pesticide residues during tobacco smoking. Chemosphere. 1987;16(2-3):521-522.